← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
talquetamab
L01FX29
Forms & Strengths
- Injection: 3 mg/1.5 mL (2 mg/mL) in a single-dose vial
- Injection: 40 mg/mL in a single-dose vial
Adult Dosing
- Step-up dosing schedule (0.06 mg/kg, 0.3 mg/kg, then 0.6 mg/kg weekly subcutaneously)
- Alternative weekly dosing: 0.4 mg/kg subcutaneously after step-up
- Alternative biweekly dosing: 0.8 mg/kg subcutaneously every 2 weeks after step-up
Pediatric Dosing
- Safety and efficacy have not been established in pediatric patients (< 18 years)
Indications
- Relapsed or refractory multiple myeloma in adult patients who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Mechanism of Action
- Bispecific T-cell engager (BiTE) antibody that binds to GPRC5D (G protein-coupled receptor class C group 5 member D) on multiple myeloma cells and CD3 on T cells, redirecting T cells to engage and eliminate myeloma cells
Contraindications
- Known hypersensitivity to talquetamab or any of its excipients
Adverse Reactions
- Cytokine release syndrome (CRS)
- Neurologic toxicity, including Immune effector cell-associated neurotoxicity syndrome (ICANS)
- Cytopenias (neutropenia, anemia, thrombocytopenia)
- Skin and nail disorders (rash, dysgeusia, nail discoloration/shedding)
- Musculoskeletal pain and fatigue
- Infections and hypogammaglobulinemia
Drug Interactions
- Live vaccines (avoid administration during and after treatment until B-cell recovery)
- CYP450 substrates with a narrow therapeutic index (cytokines released during CRS may alter CYP450 enzyme activity, requiring monitoring)
Curated Content: Needs Vetting Before Put to Clinical Use